Researchers report the 5-year survival outcomes with lisocabtagene maraleucel in heavily pretreated patients with relapsed or ...

Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...

Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published ...

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes ...

Mantle cell lymphoma is the fourth subtype of non-Hodgkin lymphoma that can be treated with this CAR T-cell therapy. Bristol Myers Squibb today announced 1 that FDA has approved lisocabtagene ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Ibrutinib may enhance lisocabtagene maraleucel efficacy in CLL patients with Richter transformation, showing an 83.3% response rate in a small case series. Four patients achieved minimal residual ...

Please provide your email address to receive an email when new articles are posted on . Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with ...